Impact of consensus molecular subtyping (CMS) on survival in the CO.26 trial of durvalumab plus tremelimumab versus best supportive care (BSC) in metastatic colorectal cancer (mCRC).

被引：0
作者：
Loree, Jonathan M.
Topham, James T.
Kennecke, Hagen Fritz
Feilotter, Harriet
Lee, Young S.
Virk, Shakeel
Kopetz, Scott
Duose, Dzifa Yawa
Manyam, Ganiraju C.
Morris, Jeffrey S.
Maru, Dipen M.
Renouf, Daniel
Jonker, Derek J.
Tu, Dongsheng
O'Callaghan, Christopher J.
Chen, Eric Xueyu
机构：
[1] Genome Sci Ctr, Vancouver, BC, Canada
[2] Providence Canc Inst, Portland, OR USA
[3] Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada
[4] AstraZeneca, Translat Med, Gaithersburg, MD USA
[5] Queens Univ, Canadian Canc Trials Grp, Kingston, ON, Canada
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Translat Mol Pathol, Houston, TX USA
[8] Univ Penn, Philadelphia, PA USA
[9] MD Anderson Canc Ctr, Houston, TX USA
[10] Univ British Columbia, Vancouver, BC, Canada
[11] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[12] Univ Hlth Network, Princess Margaret Canc Ctr, Toronto, ON, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3551
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
    Van Cutsem, E.
    Yoshino, T.
    Lenz, H-J.
    Lonardi, S.
    Falcone, A.
    Limon, M. L.
    Saunders, M. P.
    Sobrero, A.
    Maiello, E.
    Park, Y. S.
    Ferreiro Monteagudo, R.
    Hong, Y. S.
    Tomasek, J.
    Taniguchi, H.
    Ciardiello, F.
    Hocke, J.
    Oum'hamed, Z.
    Vlassak, S.
    Studeny, M.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [42] ctDNA-based mutational landscape following anti-EGFR antibodies in metastatic colorectal cancer (mCRC) to uncover novel resistance mechanisms in the CCTG CO.26 trial.
    Topham, James T.
    O'Callaghan, Christopher J.
    Feilotter, Harriet
    Kennecke, Hagen F.
    Lee, Young S.
    Li Weimin
    Banks, Kimberly
    Renouf, Daniel John
    Jonker, Derek
    Tu Dongsheng
    Chen, Eric Xueyu
    Loree, Jonathan M.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [43] The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17
    Vickers, M. M.
    Karapetis, C. S.
    Tu, D.
    O'Callaghan, C. J.
    Price, T. J.
    Tebbutt, N. C.
    Van Hazel, G.
    Shapiro, J. D.
    Pavlakis, N.
    Gibbs, P.
    Blondal, J.
    Lee, U. J. Yu Min
    Meharchand, J. M.
    Burkes, R. L.
    Rubin, S. H.
    Simes, J.
    Zalcberg, J. R.
    Moore, M. J.
    Zhu, L.
    Jonker, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Comorbidity and overall survival (OS) in cetuximab-treated patients with advanced colorectal cancer (ACRC)-Results from NCIC CTG CO.17: A phase III trial of cetuximab versus best supportive care (BSC)
    Powell, E. D.
    Asmis, T.
    Jonker, D.
    Tu, D.
    Karapetis, C.
    Jeffery, M.
    O'Callaghan, C.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [45] Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: Geographic subgroups
    Ohtsu, Atsushi
    Yoshino, Takayuki
    Wahba, Mona M.
    Benedetti, Fabio M.
    Mayer, Robert J.
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [46] Phase 3 RECOURSE trial of TAS-102 versus placebo with best supportive care in patients with metastatic colorectal cancer: European subgroup
    Falcone, A.
    Laurent, S.
    Gravalos, C.
    Benavides, M.
    Munoz, F. Longo
    Ychou, M.
    Ciardiello, F.
    Siena, S.
    Yamaguchi, K.
    Muro, K.
    Denda, T.
    Tsuji, Y.
    Tebbutt, N.
    Loehrer, P. J.
    Lenz, H. -J.
    Mayer, R. J.
    Ohtsu, A.
    Van Cutsem, E.
    ANNALS OF ONCOLOGY, 2015, 26
  • [47] Association of consensus molecular subtypes (CMS) with time to progression (TTP), progression free survival (PFS), and overall survival (OS) with second-line FOLFIRI ± regorafenib in metastatic colorectal cancer (mCRC)
    Lee, Michael Sangmin
    Selitsky, Sara R.
    Parker, Joel S.
    Auman, James Todd
    Wu, Yunhan
    Hammond, Kelli
    O'Neil, Bert
    Sanoff, Hanna Kelly
    Innocenti, Federico
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [48] Quality-adjusted survival in patients with metastatic colorectal cancer treated with fruquintinib plus best supportive care: results from FRESCO-2
    Stintzing, S.
    Tabernero, J.
    Satoh, T.
    Dasari, A.
    Lonardi, S.
    Eng, C.
    Garcia-Carbonero, R.
    Elez, E.
    Yoshino, T.
    Sobrero, A. F.
    Yao, J. C.
    Kasper, S.
    Arnold, D.
    Basic, E.
    Granold, M.
    Petschulies, M.
    Wu, L.
    Chung, Y. -C
    Chen, L.
    Yang, Z.
    Van Cutsem, E.
    ESMO OPEN, 2025, 10 (03)
  • [49] Analysis of consensus molecular subtypes (CMS) classification in the TRICOLORE trial: A randomized phase III trial of S-1 and irinotecan (IRI) plus bevacizumab (Bmab) versus mFOLFOX6 or CapeOX plus Bmab as first-line treatment for metastatic colorectal cancer (mCRC)
    Yuki, Satoshi
    Gamoh, Makio
    Denda, Tadamichi
    Takashima, Atsuo
    Takahashi, Shin
    Nakamura, Masato
    Ohori, Hisatsugu
    Yamaguchi, Tatsuro
    Kobayashi, Yoshimitsu
    Baba, Hideo
    Kotake, Masanori
    Amagai, Kenji
    Kondo, Hitoshi
    Shimada, Ken
    Sato, Atsushi
    Ishioka, Chikashi
    Komine, Keigo
    Ouchi, Kota
    Morita, Satoshi
    Komatsu, Yoshito
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [50] The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial
    Mooi, J. K.
    Wirapati, P.
    Asher, R.
    Lee, C. K.
    Savas, P.
    Price, T. J.
    Townsend, A.
    Hardingham, J.
    Buchanan, D.
    Williams, D.
    Tejpar, S.
    Mariadason, J. M.
    Tebbutt, N. C.
    ANNALS OF ONCOLOGY, 2018, 29 (11) : 2240 - 2246
12345